New drug PB shows promise for slowing excessive urination in kidney patients
NCT ID NCT05190744
First seen Jan 27, 2026 · Last updated May 13, 2026 · Updated 12 times
Summary
This study tested the drug PB to see if it can safely reduce excessive urination in people with certain kidney diseases, including inherited nephrogenic diabetes insipidus, lithium-induced kidney damage, and polycystic kidney disease treated with tolvaptan. Thirty-six adults with very high urine output took PB, and researchers measured changes in urine concentration and daily urine volume. The goal was to improve quality of life by controlling a burdensome symptom.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
Conditions
Explore the condition pages connected to this study.